EGFR and breast carcinoma: This mechanism has been demonstrated in different types of cancer cells including breast cancer, NSCLC, and head and neck squamous cell carcinoma cells, and by using different types of cancer antagonists including hormonal modulation, chemotherapeutic agents, EGFR small molecule inhibitors gefitinib and erlotinib, and AKT small molecule inhibitor AZD5363 [258, 264, 272, 275, 276].